Clinical data also suggest that anti‐PD‐1/PD‐L1 therapeutics, such as durvalumab, may improve the activity of lymphoma therapies including lenalidomide (an immunomodulatory drug), ibrutinib (a Bruton's tyrosine kinase inhibitor), bendamustine (an alkylating pro‐apoptotic chemotherapeutic), and rituximab (a monoclonal anti‐CD20 antibody) when given in combination.5, 6, 7, 8. The gene discussed is CD274; the disease is lymphoma.